SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Up 64.7% in December

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 2,800 shares, a growth of 64.7% from the December 15th total of 1,700 shares. Based on an average trading volume of 17,700 shares, the short-interest ratio is currently 0.2 days.

SAB Biotherapeutics Stock Down 33.9 %

Shares of SAB Biotherapeutics stock traded down $0.05 on Friday, hitting $0.10. The stock had a trading volume of 2,080 shares, compared to its average volume of 12,062. SAB Biotherapeutics has a 52-week low of $0.01 and a 52-week high of $0.19. The company’s 50 day moving average price is $0.07 and its 200 day moving average price is $0.05.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.